Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Endoceutics Inc.
Asia Deal Watch: Otsuka Gets Japanese Rights To Perception’s Mood Disorder Candidate
Plus deals involving I-Mab/Complix, Lupin/Endoceutics, Genome & Co/Pfizer/Merck KGaA, Genome & Co/Debiopharm, Exelixis/WuXi, Intas/Foresee, Wugen/Alpha Biosciences
Proof Suggested For DHEA Improving Pre-Menopausal Women's Sex Drive
"We've identified the patient population that would benefit from this," said Vitaly Kushnir, of the Center for Human Reproduction. Fertility Nutraceuticals-backed study shows subjects' Female Sexual Function Index scores increased by 17% for desire, 12% for arousal and 8% for lubrication.
Deal Watch: Genentech Gets Down In The Dirt With Lodo Therapeutics
Genentech and Lodo will mine the soil microbiome to discover novel therapeutics. China’s Luye licenses commercial rights to AstraZeneca’s Seroquel franchise, while Sarepta picked up rights to gene therapy candidates from Myonexus, plus an option to acquire the company.
EU CHMP OKs New Treatments For MS, Esophagitis, CMV, Hemophilia – & First Biosimilar Avastin
The EMA’s scientific committee, the CHMP, has given the green light to new treatments for multiple sclerosis, eosinophilic esophagitis, CMV, hemophilia A, and vaginal atrophy, as well as the EU’s first biosimilar version of Roche’s Avastin. The committee upheld two earlier negative opinions, and two products have been withdrawn from the assessment process.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.